| 3 | 1/1 | 返回列表 |
| 查看: 469 | 回復: 2 | |||
lijizhi79木蟲 (小有名氣)
|
[交流]
GlaxoSmithKline and Novartis, starring players in a Big Pharma deal bonanza 已有2人參與
|
|
While the chattering classes were chattering about a potential Pfizer-AstraZeneca merger yesterday, three other drug giants were putting the finishing touches on a big announcement. Novartis ($NVS), whose strategic review has been making headlines for almost a year, agreed to swap some assets with GlaxoSmithKline ($GSK) and sell its animal health business to Eli Lilly ($LLY). Altogether, the transactions are worth more than $25 billion, a decent-sized figure in the scheme of pharma M&A. Even bigger? The changes these deals will wreak at the three companies, Novartis and GSK in particular. Glaxo will be out of the cancer business. Novartis will be out of vaccines and animal health. Together, the two companies will run a consumer health joint venture with a combined $11 billion or so in sales. And Eli Lilly will have an even heftier presence in animal health, where its Elanco unit already boasts major market share. We've taken a look at the different pieces of the three-way deal frenzy in Tuesday's news coverage. Follow the links to find out more. But here are the basics: Why did Glaxo choose to get out of the cancer business, and what does Novartis get for its $16 billion? CEOs Andrew Witty and Joe Jimenez have something to say about that. What does GSK propose to do with Novartis' vaccines business, particularly its meningitis B shot Bexsero? Build scale and add sales in a business that relies on high volumes--advantages worth up to $7.1 billion in up-front and milestone payments. How will Glaxo and Novartis meld their consumer health line-ups and save money in the process? In a joint venture controlled by GSK, with well-known brand names and distribution all over the world. What will Lilly gain in picking up Novartis' animal health business for $5.4 billion? Status as the second-biggest animal health company worldwide, plus a boost to this year's top line, for starters. We have one unanswered question, though. With rumors about Novartis' strategic review swirling for months, an asset swap with GSK never came up. How did these companies keep it quiet? -- Tracy Staton |

木蟲 (正式寫手)

| 3 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 能源材料化學課題組招收碩士研究生8-10名 +4 | 脫穎而出 2026-03-16 | 12/600 |
|
|---|---|---|---|---|
|
[考研] 085601材料工程專碩求調(diào)劑 +10 | 慕寒mio 2026-03-16 | 10/500 |
|
|
[考研] 求調(diào)劑 +3 | Mqqqqqq 2026-03-19 | 3/150 |
|
|
[考研] 0817調(diào)劑 +3 | 沒有答案_ 2026-03-14 | 3/150 |
|
|
[考研] 304求調(diào)劑 +6 | 司空. 2026-03-18 | 6/300 |
|
|
[考研] 材料專業(yè)求調(diào)劑 +5 | hanamiko 2026-03-18 | 5/250 |
|
|
[考研] 344求調(diào)劑 +6 | knight344 2026-03-16 | 7/350 |
|
|
[考研] 085600材料與化工 +5 | 安全上岸! 2026-03-16 | 5/250 |
|
|
[考研] 08工科 320總分 求調(diào)劑 +5 | 梨花珞晚風 2026-03-17 | 5/250 |
|
|
[考研] 生物學071000 329分求調(diào)劑 +3 | 我愛生物生物愛?/a> 2026-03-17 | 3/150 |
|
|
[考研] 一志愿蘇州大學材料工程(085601)專碩有科研經(jīng)歷三項國獎兩個實用型專利一項省級立項 +6 | 大火山小火山 2026-03-16 | 8/400 |
|
|
[考博] 26申博 +4 | 八6八68 2026-03-16 | 4/200 |
|
|
[考研] [導師推薦]西南科技大學國防/材料導師推薦 +3 | 尖角小荷 2026-03-16 | 6/300 |
|
|
[考研] 326求調(diào)劑 +4 | 諾貝爾化學獎覬?/a> 2026-03-15 | 7/350 |
|
|
[基金申請]
今年的國基金是打分制嗎?
50+3
|
zhanghaozhu 2026-03-14 | 3/150 |
|
|
[考研] 304求調(diào)劑 +5 | 素年祭語 2026-03-15 | 5/250 |
|
|
[考研] 304求調(diào)劑 +4 | ahbd 2026-03-14 | 4/200 |
|
|
[考研] 0856專碩279求調(diào)劑 +5 | 加油加油!? 2026-03-15 | 5/250 |
|
|
[考研] 求材料調(diào)劑 085600英一數(shù)二總分302 前三科235 精通機器學習 一志愿哈工大 +4 | 林yaxin 2026-03-12 | 4/200 |
|
|
[碩博家園] 085600 260分求調(diào)劑 +3 | 天空還下雨么 2026-03-13 | 5/250 |
|